• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Adlai Nortye Ltd.

    6/27/24 6:01:06 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANL alert in real time by email
    6-K 1 tm2418173d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of June 2024

     

    Commission File Number: 001-41773

     

    Adlai Nortye Ltd.

     

    c/o PO Box 309, Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    x Form 20-F ¨ Form 40-F

     

     

     

     

     

     

    CONTENT

     

    Changes in Registrant’s Certifying Accountants

     

    Adlai Nortye Ltd. (the “Company”) was notified that Mazars USA LLP (“Mazars”), the Company’s independent registered public accounting firm, entered into a transaction with FORVIS, LLP (“FORVIS”), whereby substantially all of the partners and employees of Mazars joined FORVIS. As a result on the effective date of June 1, 2024, FORVIS LLP changed its name to Forvis Mazars, LLP (“Forvis Mazars”) and Mazars resigned as the Company’s independent registered public accounting firm. The audit committee of the Company’s board of directors has appointed Forvis Mazars as the Company’s independent registered public accounting firm effective June 1, 2024. Prior to the appointment of Forvis Mazars, Forvis Mazars was not consulted regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.

     

    The financial statements of the Company for the past two fiscal years ended December 31, 2022 and 2023 did not contain any adverse opinion or disclaimer or was qualified or modified in any respect. There were no disagreements or reportable events with Mazars, during the past two fiscal years and the subsequent period through the date of this Current Report on Form 6-K, on any matters of accounting principles or practices, financial statements disclosure, or auditing scope or procedure.

     

    The Company has provided Mazars a copy of the disclosures in this Form 6-K and has requested that Mazars furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not Mazars agrees with the Company's statements herein. A copy of the letter dated June 27, 2024 furnished by Mazars in response to that request is filed as Exhibit 99.1 to this Current Report on Form 6-K.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
       
    99.1   Letter of Mazars USA LLP dated June 27, 2024

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Adlai Nortye Ltd.
       
      By : /s/ Yang Lu
      Name : Yang Lu
      Title : Chief Executive Officer and Chairman of Board of Directors
       
    Date: June 27, 2024

     

     

     

     

    Get the next $ANL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANL

    DatePrice TargetRatingAnalyst
    6/2/2025Buy → Neutral
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    10/24/2023$30.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ANL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago. Adlai Nortye has two abstracts scheduled for presentations at AACR. "We are pleased to present the progress of our innovative pipeline at the upcoming 2025 AACR Annual Meeting. We are especially proud of our R&D capabilities in designing and developing our multi-specific immune-oncology platf

      4/10/25 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

      8/8/24 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrop

      5/23/24 9:03:04 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Leadership Updates

    Live Leadership Updates

    See more
    • Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

      8/8/24 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear

      3/29/24 6:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adlai Nortye Ltd.

      SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)

      3/4/24 4:02:34 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adlai Nortye Ltd. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral

      6/2/25 11:24:27 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

      H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00

      9/4/24 7:16:56 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00

      10/24/23 6:10:09 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    SEC Filings

    See more
    • SEC Form 6-K filed by Adlai Nortye Ltd.

      6-K - Adlai Nortye Ltd. (0001944552) (Filer)

      5/30/25 8:00:01 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 20-F/A filed by Adlai Nortye Ltd.

      20-F/A - Adlai Nortye Ltd. (0001944552) (Filer)

      5/9/25 7:58:51 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Adlai Nortye Ltd.

      20-F - Adlai Nortye Ltd. (0001944552) (Filer)

      4/30/25 4:01:34 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care